---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-001706"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2022-03-08T23:59:59+00:00"
generated_at: "2026-06-27T00:59:11.583229+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika reports Q4 2021 revenue $35.8M (+10% YoY); full year $147.8M (+13%); guides FY2022 low-to-mid single digit growth

## Summary
- Q4 2021 revenue $35.8M (+10% YoY); net loss $5.8M ($0.40 diluted) vs $15.7M loss prior year.
- Full-year 2021 revenue $147.8M (+13% YoY); net income $4.1M ($0.28 diluted) vs $24.0M loss in 2020.
- Adjusted net loss Q4 $3.2M ($0.23 diluted) vs adjusted net income $1.7M prior year; adjusted EBITDA loss $0.2M vs $4.0M.
- FY2022 guidance: revenue growth low-to-mid single digit; Joint Preservation mid-single to low-double digit, OA Pain low-single digit.
- Cash balance $94.4M; operating cash flow $9.0M for full year; completed enrollment of Cingal pilot trial.

## SEC filing metadata
- accession: 0001171843-22-001706
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2022-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184322001706/0001171843-22-001706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184322001706/f8k_030822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-001706
- JSON: https://secwatch.observer/filing/0001171843-22-001706.json
- Plain text: https://secwatch.observer/filing/0001171843-22-001706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.